tiprankstipranks
Advertisement
Advertisement

ORKA Stock Latest News

3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts
Market News3 Healthcare Stocks with Strong Upside to Consider in July 2026, According to Analysts
10d ago
BSX
INSM
Oruka Therapeutics falls -8.1%
PremiumThe Fly
Oruka Therapeutics falls -8.1%
12d ago
ORKA
Oruka Therapeutics price target raised to $130 from $100 at UBS
PremiumThe Fly
Oruka Therapeutics price target raised to $130 from $100 at UBS
13d ago
ORKA
BTIG says others may be interested in Apogee Therapeutics
PremiumThe Fly
BTIG says others may be interested in Apogee Therapeutics
22d ago
JNJ
NVS
Oruka Therapeutics Shareholders Back Governance and Executive Pay
PremiumCompany Announcements
Oruka Therapeutics Shareholders Back Governance and Executive Pay
1M ago
8K
ORKA
Kapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged
PremiumRatingsKapoor Reiterates Buy on Oruka Therapeutics as Pipeline Advances; Keeps $120 Price Target Unchanged
1M ago
ORKA
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
Premium
Company Announcements
Oruka Therapeutics Expands IL-23 License, Adds Dosing Limits
1M ago
8K
ORKA
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
Premium
Ratings
Oruka: Strong ORKA-001 Clinical Profile and Pipeline Momentum Support Reiterated Buy Rating and Unchanged $120 Price Target
2M ago
ORKA
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
PremiumRatings
Julian Harrison Reiterates Buy on Oruka Therapeutics, Maintains $151 Price Target on Strong Clinical Profile and Cash Position
2M ago
ORKA
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
PremiumRatings
Oruka Initiated With Buy on Best-in-Class ORKA-001 Psoriasis Data, Strong Cash Position, and Multi-Billion-Dollar Upside Potential
2M ago
ORKA
Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)
PremiumThe Fly
Oruka Therapeutics reports Q1 EPS (48c), consensus (54c)
2M ago
ORKA
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
PremiumThe Fly
Halozyme licenses Hypercon technology to Oruka Therapeutics in psoriasis
2M ago
HALO
ORKA
Oruka Therapeutics Completes Public Equity Offering Under Shelf
PremiumCompany AnnouncementsOruka Therapeutics Completes Public Equity Offering Under Shelf
2M ago
8K
ORKA
Oruka Therapeutics price target raised to $120 from $109 at Leerink
Premium
The Fly
Oruka Therapeutics price target raised to $120 from $109 at Leerink
2M ago
ORKA
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
Premium
The Fly
Oruka Therapeutics price target raised to $120 from $75 at H.C. Wainwright
3M ago
ORKA
Oruka Therapeutics $700M Secondary priced at $72.50
PremiumThe Fly
Oruka Therapeutics $700M Secondary priced at $72.50
3M ago
ORKA
Oruka Therapeutics price target raised to $100 from $75 at UBS
PremiumThe Fly
Oruka Therapeutics price target raised to $100 from $75 at UBS
3M ago
ORKA
Oruka Therapeutics announces $500M common stock, warrants offering
PremiumThe Fly
Oruka Therapeutics announces $500M common stock, warrants offering
3M ago
ORKA
Oruka Therapeutics price target raised to $131 from $71 at Clear Street
PremiumThe Fly
Oruka Therapeutics price target raised to $131 from $71 at Clear Street
3M ago
ORKA
Morning News Wrap-Up, 4/27/26: Today’s Biggest Stock Market Stories!
PremiumMarket NewsMorning News Wrap-Up, 4/27/26: Today’s Biggest Stock Market Stories!
3M ago
AMD
DIA
Oruka Therapeutics rises 19.0%
Premium
The Fly
Oruka Therapeutics rises 19.0%
3M ago
ORKA
Oruka Therapeutics price target raised to $160 from $78 at Barclays
Premium
The Fly
Oruka Therapeutics price target raised to $160 from $78 at Barclays
3M ago
ORKA

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >